| [1] |
|
| [2] |
Ye M, Lin Y, Pan S, et al. Applications of multi-omics approaches for exploring the molecular mechanism of ovarian carcinogenesis[J]. Front Oncol, 2021, 11: 745808. DOI: 10.3389/fonc.2021.745808.
|
| [3] |
Harbin LM, Gallion HH, Allison DB, et al. Next generation sequencing and molecular biomarkers in ovarian cancer：an opportunity for targeted therapy[J]. Diagnostics, 2022, 12(4): 842. DOI: 10.3390/diagnostics12040842.
|
| [4] |
Simona S, Simona DS, Brunella P, et al. Next-generation sequencing: advances and applications in cancer diagnosis[J]. Oncotargets Ther, 2016, 9: 7355-7365. DOI: 10.2147/OTT.S99807.
|
| [5] |
Pantaleo MA. Next generation sequencing (NGS) in oncology: lights and shadows[J]. Cancer Breaking News, 2016, 4(1): 17-19. DOI: 10.19156/cbn.2016.0004.
|
| [6] |
Hwang S, Woo S, Kang B, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer[J]. J Hepatol, 2025, 82(4): 649-657. DOI: 10.1016/j.jhep.2024.10.020.
|
| [7] |
Scalise M, Foxall MK, Thigpen H, et al. Test me now or, test me later: prospective study of molecular testing in ovarian cancer[J]. Gynecol Oncol, 2021, 162: S287-S287. DOI: 10.1016/s0090-8258(21)01196-3.
|
| [8] |
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011, 67(26): 2473-2483. DOI: 10.1097/OGX.0b013e3182547170.
|
| [9] |
Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial[J]. Ann Oncol, 2023, 34(8): 681-692. DOI: 10.1016/j.annonc.2023.05.005.
|
| [10] |
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012, 30(17): 2039-2045. DOI: 10.1200/JCO.2012.42.0505.
|
| [11] |
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13): 1302-1308. DOI: 10.1200/JCO.2013.51.4489.
|
| [12] |
Chelariu-Raicu A, Mahner S, Nadine K, et al. Integrating antibody drug conjugates in the management of gynecologic cancers[J]. Int J Gynecol Cancer, 2023, 33(3): 420-429. DOI: 10.1136/ijgc-2022-003701.
|
| [13] |
Mcnamara B, Greenman M, Pebley N, et al. Antibody-drug conjugates (ADC) in HER2/neu-positive gynecologic tumors[J]. Molecules, 2023, 28(21): 14-14. DOI: 10.3390/molecules28217389.
|
| [14] |
Goyne HE, Cannon MJ. The case for HER2/neu as a therapeutic target for gynecologic malignancies[J]. Immunotherapy, 2012, 4(8): 781-784. DOI: 10.2217/imt.12.71.
|
| [15] |
Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase Ⅰb trial[J]. Lancet Oncol, 2019, 20(4): 570-580. DOI: 10.1016/S1470-2045(18)30905-7.
|
| [16] |
Farley JH, Brady WE, O′Malley D, et al. A phase Ⅱ evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: an NRG oncology trial[J]. Gynecol Oncol, 2022, 167(3): 423-428. DOI: 10.1016/j.ygyno.2022.10.006.
|
| [17] |
Westin S, Kurnit K, Fellman B, et al. SOLAR: phase Ⅰb dose expansion of selumetinib (MEK inhibitor) and OLAparib (PARP inhibitor) combination in solid tumors with RAS pathway alterations and in PARP inhibitor-resistant ovarian cancer (LBA 9)[J]. Gynecol Oncol, 2023, 176(Suppl 1): S33. DOI: 10.1016/j.ygyno.2023.06.511.
|
| [18] |
Yunianto I, Currie M, Chitcholtan K, et al. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer[J]. J Obstet Gynaecol Res, 2023, 49(11): 2563-2574. DOI: 10.1111/jog.15761.
|
| [19] |
|
| [20] |
Peng Z, Li H, Gao Y, et al. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2024, 25(10): 1288-1297. DOI: 10.1016/S1470-2045(24)00437-6.
|